CTRP3 is a coronary artery calcification biomarker and protects against vascular calcification by inhibiting β-catenin nuclear translocation to prevent vascular smooth muscle cell osteogenic differentiation

Liu, Demin; Cui, Xiaowei; Lu, Rui; Hu, Haijuan; Gu, Guoqiang

doi:10.1016/j.jjcc.2021.10.018

Cited by 5 publications

(2 citation statements)

References 31 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…A growing body of evidence indicates that decreased serum levels of CTRP3 are associated with increased risk of various cardiovascular diseases, such as intracerebral hemorrhage [9], myocardium ischemia-reperfusion injury [16], and vascular calci cation [17]. Similarly, lower levels of CTRP3 are found to be detrimental to retinopathy and nephropathy in diabetic patients [18,19].…”

Section: Discussionmentioning

confidence: 99%

Lower serum CTRP3 is related to more severe distal symmetric polyneuropathy in type 2 diabetic patients

Han,

Hu,

Guo

et al. 2024

Preprint

View full text Add to dashboard Cite

Background: Distal symmetric polyneuropathy (DSPN) is one of the most common chronic complications in patients with type 2 diabetes mellitus (T2DM). Our previous study found that serum C1q tumor necrosis factor-related protein 3 (CTRP3) levels were decreased in type 2 diabetic patients. Thus, this study was designed to reveal the relationship between lower serum CTRP3 and the prevalence and severity of DSPN. Methods: A total of 178 cases of patients with T2DM were enrolled in the study. The subjects were divided into DSPN group (n=89) and non-DSPN group (n=89). Both the anthropometric parameters and neurologic symptoms were recorded. Also, neurologic signs, neuropathy symptom score (NSS) and neuropathy disability score (NDS) were measured. Biochemical indexes, fasting insulin, and C peptide were detected. Serum CTRP3 concentrations were assayed by ELISA method. Results: Serum CTRP3 levels decreased significantly in DSPN group compared with non-DSPN group (P<0.05). CTRP3 was negatively associated with the number of positive signs, NSS score, and NDS score in patients with DSPN (all P<0.05). Interestingly, the higher the score of NSS or NDS, the lower the levels of serum CTRP3 (all P<0.05). Moreover, the patients with lower CTRP3 levels (<7.58ng/ml) had higher positive rate of neurologic signs (all P<0.05). Binary logistic regression analysis showed that CTRP3 independently predicted the occurrence of DSPN (β= -0.316, P<0.001). ROC curve analysis displayed that the best cut-off value of CTRP3 for the prediction of DSPN was 7.55ng/ml (sensitivity 78.7%, specificity 79.8%), and the area under the curve (AUC) was 0.763 (95% CI 0.689-0.838, P<0.001). Conclusion: Lower serum CTRP3 is a strong predictor for the occurrence and progression of DSPN in Chinese patients with T2DM.

show abstract

Section: Discussionmentioning

confidence: 99%

Lower serum CTRP3 is related to more severe distal symmetric polyneuropathy in type 2 diabetic patients

Han,

Hu,

Guo

et al. 2024

Preprint

View full text Add to dashboard Cite

show abstract

“…3,4) Coronary computed tomography angiography has been widely used as a non-invasive diagnostic modality to assess patients with suspected coronary artery disease, 5) and CAC is an important risk factor for cardiovascular events. 6) The CAC score has been shown to have sensitivity of 84% for predicting coronary artery disease, and the level of vascular calcification has been found to correlate well with luminal stenosis. Increased myocardial calcium content and vascular calcification have been shown to have a strong positive correlation with elevated Ca-P product and inverse correlation with left ventricular ejection fraction (LVEF).…”

mentioning

confidence: 99%

Calcium-Phosphorus Product Is Associated with Adverse Prognosis in Hospitalized Patients with Heart Failure and Chronic Kidney Disease

Abe,

Yoshihisa,

Oohara

et al. 2024

Int. Heart J.

View full text Add to dashboard Cite

It has been reported that high levels of calcium-phosphorus (Ca-P) product are an indicator of coronary calcification and mortality risk in patients undergoing chronic hemodialysis. In the present study, we aimed to evaluate the significance of Ca-P product to predict the prognosis of patients with heart failure (HF) and chronic kidney disease (CKD). We conducted a prospective observational study of 793 patients with decompensated HF and CKD, and measured the value of Ca-P product. The cut-off value was obtained from the survival classification and regression tree (CART) analysis to predict post-discharge all-cause mortality and/or worsening HF, and the patients were divided into 2 groups: a high group (Ca-P product > 28, n = 594) and a low group (Ca-P product !28, n = 199). We compared the patient baseline characteristics and post-discharge prognosis between the 2 groups. The age as well as the prevalence of male sex, ischemic etiology, and anemia were significantly higher in the low group than in the high group. In contrast, there was no difference in echocardiographic parameters between the 2 groups. In the Kaplan-Meier analysis (mean follow-up 1089 days), all-cause mortality and/or worsening HF event rates were higher in the low group than in the high group (log-rank P = 0.001). In the multivariable Cox proportional hazard analysis, lower Ca-P product was found to be an independent predictor of all-cause mortality and/or worsening HF (hazard ratio 0.981, P = 0.031). Lower Ca-P product predicts adverse prognosis in patients with HF and CKD.

show abstract

Low serum CTRP3 is related to more severe distal symmetric polyneuropathy in type 2 diabetes patients

Han,

Hu,

Guo

et al. 2024

Hormones

View full text Add to dashboard Cite

CTRP3 is a coronary artery calcification biomarker and protects against vascular calcification by inhibiting β-catenin nuclear translocation to prevent vascular smooth muscle cell osteogenic differentiation

Cited by 5 publications

References 31 publications

Lower serum CTRP3 is related to more severe distal symmetric polyneuropathy in type 2 diabetic patients

Lower serum CTRP3 is related to more severe distal symmetric polyneuropathy in type 2 diabetic patients

Calcium-Phosphorus Product Is Associated with Adverse Prognosis in Hospitalized Patients with Heart Failure and Chronic Kidney Disease

Low serum CTRP3 is related to more severe distal symmetric polyneuropathy in type 2 diabetes patients

Contact Info

Product

Resources

About